Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22309295 | 1.00 | TUBB1 (0.51) | TUBB1AKT1MMP1MMP3ADAMTS4 | |
| SCHEMBL20732393 | 1.00 | TUBB1 (0.51) | TUBB1AKT1MMP1MMP3ADAMTS4 | |
| SCHEMBL22308011 | 1.00 | TUBB1 (0.51) | TUBB1AKT1MMP1MMP3ADAMTS4 | |
| SCHEMBL22309307 | 0.94 | TUBB1 (0.52) | TUBB1AKT1MMP3 | |
| SCHEMBL22309303 | 0.94 | TUBB1 (0.52) | TUBB1AKT1MMP3 | |
| SCHEMBL22309304 | 0.94 | TUBB1 (0.52) | TUBB1AKT1MMP3 | |
| SCHEMBL20732389 | 0.94 | TUBB1 (0.52) | TUBB1AKT1MMP3 | |
| SCHEMBL20732398 | 0.94 | TUBB1 (0.52) | TUBB1AKT1MMP3 | |
| SCHEMBL24410013 | 0.93 | TUBB1 (0.47) | TUBB1AKT1MMP1MMP3 | |
| SCHEMBL24410018 | 0.93 | TUBB1 (0.47) | TUBB1AKT1MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| WO-2019031614-A1 | ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE | 大日本住友製薬株式会社 | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TUBB1 119/4885AKT1 3768/4885MMP1 1978/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885AKT1 1702/4885MMP1 2483/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885AKT1 1702/4885MMP1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.